Skip to content

Study · Not a test of the peptide alone · 2026

1 result

Fluorous oligoarginines as supra-enhancers for intracellular and transdermal peptide delivery.

Rong G, Fan Q, Chen K, Cheng Y, Hu J

Bioactive materials30 Dec 2025Cited by 1 (Europe PMC)

PMID41551769 (opens in a new tab)PMCIDPMC12804165 (opens in a new tab)DOI10.1016/j.bioactmat.2025.12.027 (opens in a new tab)PepBankPUB-41551769
Read at sourcePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Argireline (acetyl hexapeptide-8) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Argireline (acetyl hexapeptide-8).

  1. 01LabNot a test of Argireline (acetyl hexapeptide-8) aloneEx vivo tissueActivity measurement

    In transdermal delivery experiments, FR6 enhanced acetyl hexapeptide‑8 penetration.

    In plain wordsIn lab tests, FR6 enhanced acetyl hexapeptide‑8 penetration.

    Peptide
    Argireline (acetyl hexapeptide-8)
    Outcome
    IncreaseAcetyl hexapeptide-8 penetration
    Study

    n: not reported in source

    transdermal peptide delivery
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    More importantly, FR6 demonstrates remarkable potential for transdermal delivery of peptide drugs, effectively enhancing the penetration of peptides like acetyl hexapeptide-8 for treating UVB-induced skin photoaging.

    In this study, Argireline (acetyl hexapeptide-8) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Argireline (acetyl hexapeptide-8).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.